Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

NCT03428126 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Malignant Neoplasms of Digestive Organs
Colorectal Cancer
Colon Cancer

Interventions

DRUG: Durvalumab
DRUG: Trametinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]